Navigating First-Line Treatment Selection in a Crowded Biomarker Landscape
ByEric Singhi, MD,Bruna Pellini, MD,Estelamari Rodriguez, MD, MPH,Gregory Riedlinger, MD, PhD,Idalmis Hernandez. NP
Published: | Updated:
With 4 ROS1-directed TKIs now in the mix, community oncologists need a clear framework for sequencing and CNS considerations in this rare NSCLC subset.